Compare Panacea Biotech with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs PROCTER & GAMBLE HEALTH - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH PROCTER & GAMBLE HEALTH PANACEA BIOTECH/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 16.5 15.7 105.0% View Chart
P/BV x 6.4 6.3 101.6% View Chart
Dividend Yield % 0.0 7.5 -  

Financials

 PANACEA BIOTECH   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
PANACEA BIOTECH/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs3543,549 10.0%   
Low Rs1381,301 10.6%   
Sales per share (Unadj.) Rs74.6511.4 14.6%  
Earnings per share (Unadj.) Rs6.761.3 10.9%  
Cash flow per share (Unadj.) Rs15.574.0 20.9%  
Dividends per share (Unadj.) Rs0440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs57.2927.8 6.2%  
Shares outstanding (eoy) m61.2516.60 369.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.34.7 69.5%   
Avg P/E ratio x36.839.6 93.0%  
P/CF ratio (eoy) x15.932.8 48.4%  
Price / Book Value ratio x4.32.6 164.4%  
Dividend payout %0717.9 0.0%   
Avg Mkt Cap Rs m15,06140,257 37.4%   
No. of employees `0002.31.1 204.1%   
Total wages/salary Rs m1,4711,313 112.0%   
Avg. sales/employee Rs Th1,973.67,486.7 26.4%   
Avg. wages/employee Rs Th635.61,157.6 54.9%   
Avg. net profit/employee Rs Th176.8897.2 19.7%   
INCOME DATA
Net Sales Rs m4,5678,490 53.8%  
Other income Rs m45244 18.4%   
Total revenues Rs m4,6128,734 52.8%   
Gross profit Rs m2,0301,482 137.0%  
Depreciation Rs m540211 255.7%   
Interest Rs m1,0480-   
Profit before tax Rs m4861,514 32.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m77563 13.7%   
Profit after tax Rs m4091,017 40.2%  
Gross profit margin %44.417.5 254.7%  
Effective tax rate %15.937.1 42.7%   
Net profit margin %9.012.0 74.7%  
BALANCE SHEET DATA
Current assets Rs m2,41515,343 15.7%   
Current liabilities Rs m9,0771,960 463.1%   
Net working cap to sales %-145.9157.6 -92.6%  
Current ratio x0.37.8 3.4%  
Inventory Days Days6549 133.5%  
Debtors Days Days7128 249.3%  
Net fixed assets Rs m8,3331,209 689.1%   
Share capital Rs m61166 36.9%   
"Free" reserves Rs m3,44315,235 22.6%   
Net worth Rs m3,50415,401 22.8%   
Long term debt Rs m4610-   
Total assets Rs m13,75517,595 78.2%  
Interest coverage x1.5NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.30.5 68.8%   
Return on assets %10.65.8 183.2%  
Return on equity %11.76.6 176.7%  
Return on capital %38.710.3 377.2%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,2031,636 73.5%   
Fx outflow Rs m4674,368 10.7%   
Net fx Rs m736-2,732 -27.0%   
CASH FLOW
From Operations Rs m1,049-1,304 -80.4%  
From Investments Rs m-5412,697 -0.4%  
From Financial Activity Rs m-1,011-301 336.6%  
Net Cashflow Rs m-2011,093 -0.2%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 0.6 18.2 3.3%  
FIIs % 1.3 1.0 130.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 29.1 81.1%  
Shareholders   10,259 28,591 35.9%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   GLENMARK PHARMA  FULFORD INDIA  ORCHID PHARMA  DIVIS LABORATORIES  UNICHEM LAB  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Higher, Dow Futures Up by 86 Points(12:30 pm)

Share markets in India are presently trading on a strong note. The BSE Sensex is trading up by 379 points, up 0.8% at 49,585 levels.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


May 10, 2021 01:18 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS